In bronchiectasis, highly symptomatic patients have a greater risk of exacerbations and may benefit from long-term macrolide treatment.

Brinsupri is an oral inhibitor of dipeptidyl peptidase 1 and targets neutrophilic serine proteases, which mediate ...

Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 adults nationwide, is necessary to slow disease progression and help prevent further damage to ...

What are the current gaps in knowledge regarding the management of bronchiectasis? What is your typical treatment approach to managing bronchiectasis? What patient-specific factors impact your ...

Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary ...

Mucoactive agents did little to stave off pulmonary exacerbations of non-cystic fibrosis bronchiectasis, the CLEAR trial showed. In the two-by-two factorial trial testing hypertonic saline and ...

Panelists discuss how bronchiectasis is more common than previously thought, with growing awareness, research, and specialized centers improving diagnosis and treatment options, though challenges ...

ERS issues new bronchiectasis guidelines to improve patient care, standardise treatment, and reduce variability in global ...

Bronchiectasis is a chronic condition of the respiratory system that is due to abnormal widening of the airways as a consequence of an initial damaging factor. The bronchi, located between the trachea ...

Dublin, Dec. 09, 2024 (GLOBE NEWSWIRE) -- The "Bronchiectasis - Market Insight, Epidemiology and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report ...

If you receive a denial letter from your insurer, seek legal advice before appealing the decision, says a leading disability ...

Bronchiectasis develops early in the course of cystic fibrosis, being detectable in infants as young as 10 weeks of age, and is persistent and progressive. We sought to determine risk factors for the ...